» Articles » PMID: 39296713

N6-methyladenine RNA Methylation Epigenetic Modification and Diabetic Microvascular Complications

Overview
Specialty Endocrinology
Date 2024 Sep 19
PMID 39296713
Authors
Affiliations
Soon will be listed here.
Abstract

N6-methyladensine (mA) has been identified as the best-characterized and the most abundant mRNA modification in eukaryotes. It can be dynamically regulated, removed, and recognized by its specific cellular components (respectively called "writers," "erasers," "readers") and have become a hot research field in a variety of biological processes and diseases. Currently, the underlying molecular mechanisms of mA epigenetic modification in diabetes mellitus (DM) and diabetic microvascular complications have not been extensively clarified. In this review, we focus on the effects and possible mechanisms of mA as possible potential biomarkers and therapeutic targets in the treatment of DM and diabetic microvascular complications.

Citing Articles

RNA Modification in Metabolism.

Liu Y, Sun Z, Gui D, Zhao Y, Xu Y MedComm (2020). 2025; 6(3):e70135.

PMID: 40066222 PMC: 11892166. DOI: 10.1002/mco2.70135.


Exploring the methyl-verse: Dynamic interplay of epigenome and m6A epitranscriptome.

Pilala K, Panoutsopoulou K, Papadimitriou M, Soureas K, Scorilas A, Avgeris M Mol Ther. 2024; 33(2):447-464.

PMID: 39659016 PMC: 11852398. DOI: 10.1016/j.ymthe.2024.12.003.

References
1.
Du H, Zhao Y, He J, Zhang Y, Xi H, Liu M . YTHDF2 destabilizes m(6)A-containing RNA through direct recruitment of the CCR4-NOT deadenylase complex. Nat Commun. 2016; 7:12626. PMC: 5007331. DOI: 10.1038/ncomms12626. View

2.
Zhang W, Zhang S, Dong C, Guo S, Jia W, Jiang Y . A bibliometric analysis of RNA methylation in diabetes mellitus and its complications from 2002 to 2022. Front Endocrinol (Lausanne). 2022; 13:997034. PMC: 9492860. DOI: 10.3389/fendo.2022.997034. View

3.
De Jesus D, Zhang Z, Kahraman S, Brown N, Chen M, Hu J . mA mRNA Methylation Regulates Human β-Cell Biology in Physiological States and in Type 2 Diabetes. Nat Metab. 2019; 1(8):765-774. PMC: 6924515. DOI: 10.1038/s42255-019-0089-9. View

4.
Yang K, Sun J, Zhang Z, Xiao M, Ren D, Liu S . Reduction of mRNA mA associates with glucose metabolism via YTHDC1 in human and mice. Diabetes Res Clin Pract. 2023; 198:110607. DOI: 10.1016/j.diabres.2023.110607. View

5.
Elafros M, Andersen H, Bennett D, Savelieff M, Viswanathan V, Callaghan B . Towards prevention of diabetic peripheral neuropathy: clinical presentation, pathogenesis, and new treatments. Lancet Neurol. 2022; 21(10):922-936. PMC: 10112836. DOI: 10.1016/S1474-4422(22)00188-0. View